BioWorld

March 5, 2010

GTx Mum as Merck Discontinues Phase II SARM Ostarine/MK-2866

Four months after GTx Inc. suffered a devastating FDA setback with lead program toremifene, the biotech's second program - Phase II muscle loss drug Ostarine/MK-2866 - has been discontinued by partner Merck and Co. Inc. (BioWorld Today) Read More

Senators Agree on Language in Long-Debated Patent Reform

News Times Three: SpePharm Adds Product, Partner, Money

Vaxart Raises $12.5M in Series B to Take Oral Vaccine into Clinic

Columbia Labs Getting $92.5M in Watson Progesterone Deal

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...